首站-论文投稿智能助手
典型文献
Inhibition of ASCT2 induces hepatic stellate cell senescence with modified proinflammatory secretome through an IL-1α/NF-κB feedback pathway to inhibit liver fibrosis
文献摘要:
Senescence of activated hepatic stellate cells(aHSCs)is a stable growth arrest that is impli-cated in liver fibrosis regression.Senescent cells often accompanied by a multi-faceted senescence-asso-ciated secretory phenotype(SASP).But little is known about how alanine-serine-cysteine transporter type-2(ASCT2),a high affinity glutamine transporter,affects HSC senescence and SASP during liver fibrosis.Here,we identified ASCT2 is mainly elevated in aHSCs and positively correlated with liver fibrosis in human and mouse fibrotic livers.We first discovered ASCT2 inhibition induced HSCs to senes-cence in vitro and in vivo.The proinflammatory SASP were restricted by ASCT2 inhibition at senescence initiation to prevent paracrine migration.Mechanically,ASCT2 was a direct target of glutaminolysis-dependent proinflammatory SASP,interfering IL-1α/NF-κB feedback loop via interacting with precursor IL-1α at Lys82.From a translational perspective,atractylenolide Ⅲ is identified as ASCT2 inhibitor through directly bound to Asn230 of ASCT2.The presence of-OH group in atractylenolide Ⅲ is sug-gested to be favorable for the inhibition of ASCT2.Importantly,atractylenolide Ⅲ could be utilized to treat liver fibrosis mice.Taken together,ASCT2 controlled HSC senescence while modifying the proin-flammatory SASP.Targeting ASCT2 by atractylenolide Ⅲ could be a therapeutic candidate for liver fibrosis.
文献关键词:
作者姓名:
Feixia Wang;Zhanghao Li;Li Chen;Ting Yang;Baoyu Liang;Zili Zhang;Jiangjuan Shao;Xuefen Xu;Guoping Yin;Shijun Wang;Hai Ding;Feng Zhang;Shizhong Zheng
作者机构:
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica,School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing 210023,China;Department of Anesthesiology,Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine,Nanjing 210003,China;College of Traditional Chinese Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250035,China;Department of General Surgery,Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine,Nanjing 210003,China
引用格式:
[1]Feixia Wang;Zhanghao Li;Li Chen;Ting Yang;Baoyu Liang;Zili Zhang;Jiangjuan Shao;Xuefen Xu;Guoping Yin;Shijun Wang;Hai Ding;Feng Zhang;Shizhong Zheng-.Inhibition of ASCT2 induces hepatic stellate cell senescence with modified proinflammatory secretome through an IL-1α/NF-κB feedback pathway to inhibit liver fibrosis)[J].药学学报(英文版),2022(09):3618-3638
A类:
aHSCs,Senescent,Lys82,atractylenolide,Asn230
B类:
Inhibition,ASCT2,induces,hepatic,stellate,senescence,modified,proinflammatory,secretome,through,feedback,pathway,fibrosis,Senescence,activated,cells,stable,growth,arrest,that,impli,cated,regression,often,accompanied,by,multi,faceted,asso,ciated,secretory,phenotype,SASP,But,little,known,about,how,alanine,serine,cysteine,transporter,high,affinity,glutamine,affects,during,Here,identified,mainly,elevated,positively,correlated,human,mouse,fibrotic,livers,We,first,discovered,inhibition,induced,vitro,vivo,were,restricted,initiation,prevent,paracrine,migration,Mechanically,was,target,glutaminolysis,dependent,interfering,loop,via,interacting,precursor,From,translational,perspective,inhibitor,directly,bound,presence,group,sug,gested,be,favorable,Importantly,could,utilized,treat,mice,Taken,together,controlled,while,modifying,Targeting,therapeutic,candidate
AB值:
0.498704
相似文献
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Pharmacological inhibition of MyD88 suppresses inflammation in tubular epithelial cells and prevents diabetic nephropathy in experimental mice
Qiu-yan Zhang;Su-jing Xu;Jian-chang Qian;Li-bin Yang;Peng-qin Chen;Yi Wang;Xiang Hu;Ya-li Zhang;Wu Luo;Guang Liang-Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Medical Research Center,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou 325035,China;School and Hospital of Stomatology,Wenzhou Medical University,Wenzhou 325027,China;Department of Endocrinology,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou 325035,China;School of Pharmaceutical Sciences,Hangzhou Medical College,Hangzhou 311399,China;Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325001,China
Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway
Yi-kuan Wu;Zheng-nan Ren;Sheng-long Zhu;Yun-zhou Wu;Gang Wang;Hao Zhang;Wei Chen;Zhao He;Xian-long Ye;Qi-xiao Zhai-State Key Laboratory of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Food Science and Technology,Jiangnan University,Wuxi 214122,China;School of Medicine,Jiangnan University,Wuxi 214122,China;College of Life Science,Northeast Agricultural University,Harbin 150038,China;National Engineering Research Center for Functional Food,Jiangnan University,Wuxi 214122,China;Shandong Key Laboratory of Endocrinology and Lipid Metabolism,Jinan 250021,China;School of Medicine,Shandong University,Jinan 250012,China;Ganjiang Chinese Medicine Innovation Center,Nanchang 330000,China
NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury
Zhi-yong Xie;Wei Dong;Li Zhang;Meng-jie Wang;Zhen-meng Xiao;Yu-hua Zhang;Wan-xin Shi;Ying Huang;Yan Yang;Cui-li Li;Lei Fu;Xing-chen Zhao;Rui-zhao Li;Zhi-lian Li;Yuan-han Chen;Zhi-ming Ye;Shuang-xin Liu;Zheng Dong;Xin-ling Liang-The Second School of Clinical Medicine,Southern Medical University,Guangzhou 510515,China;Division of Nephrology,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou 510080,China;School of Medicine,South China University of Technology,Guangzhou 510006,China;Department of Cellular Biology and Anatomy,Medical College of Georgia at Augusta University,Augusta,GA,USA;Department of Medical Research,Charlie Norwood Veterans Affairs Medical Center,Augusta,GA,USA
Critical role of PAFR/YAP1 positive feedback loop in cardiac fibrosis
Tian-yu Li;Wei Su;Liang-liang Li;Xiao-guang Zhao;Na Yang;Jia-xin Gai;Xin Lv;Jing Zhang;Meng-qin Huang;Qing Zhang;Wei-hang Ji;Xiao-ying Song;Yu-hong Zhou;Xue-lian Li;Hong-li Shan;Hai-hai Liang-Department of Pharmacology(State-Province Key Laboratories of Biomedicine-Pharmaceutics of China,Key Laboratory of Cardiovascular Research,Ministry of Education),College of Pharmacy,Harbin Medical University,Harbin 150081,China;Zhuhai People's Hospital,Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment,Zhuhai Hospital Affiliated with Jinan University,Jinan University,Zhuhai 519000,China;Department of Cardiology,The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Noncoding RNA,Institute for Frontier Medical Technology,Shanghai University of Engineering Science,Shanghai 201620,China;Research Unit of Noninfectious Chronic Diseases in Frigid Zone(2019RU070),Chinese Academy of Medical Sciences,Harbin 150081,China
Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells
Hao Shen;Han Yu;Qian-yu Li;Ya-ting Wei;Jing Fu;Hui Dong;Dan Cao;Lin-na Guo;Lei Chen;Yuan Yang;Ying Xu;Meng-chao Wu;Hong-yang Wang;Yao Chen-International Cooperation Laboratory on Signal Transduction,National Center for Liver Cancer,Ministry of Education Key Laboratory on signaling Regulation and Targeting Therapy of Liver Cancer,Shanghai Key Laboratory of Hepato-biliary Tumor Biology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University/NAVAL Medical University,Shanghai 200433,China;Department of Pathology,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Institute of Metabolism and Integrative Biology,Fudan University,Shanghai 200438,China;Third Department of Hepatic Surgery,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai 200433,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。